One World Products, Inc.

OWPC
About the company

One World Products, Inc. engages in the provision of renewable and sustainable materials. It processes rubber, cellulose, hemp, and a range of bio-feedstocks into composites for automotive, industrial, and food packaging. The company was founded in 2018 and is headquartered in Las Vegas, Nevada.

Country: United StatesPrice: $0.00Market Cap: $36,032

Investment snapshot

6%positive consensus
Scored 1d ago

Positive

1

BUY / PASS

Neutral / negative

2 / 13

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedPASSFAILFAILFAILFAILFAILFAILFAILFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2025-09-30 · Balance sheet at 2025-09-30 · Annual history · FY 2024

Latest source filing: 2026-01-02

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-06-03

Score computed: 2026-11-14

Annual history · FY 2024 · TTM ended 2025-09-30

Latest source filing: 2026-01-02

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-06-03

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-06-03

Score computed: 2026-11-14

Annual history · FY 2024 · TTM ended 2025-09-30 · Balance sheet at 2025-09-30 · Market data at 2026-11-01

Latest source filing: 2026-01-02

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2024

Latest source filing: 2025-06-03

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2024

Latest source filing: 2025-06-03

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2025-06-03

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2025-06-03

Score computed: 2026-11-14

Annual history · FY 2024 · TTM ended 2025-09-30 · Market data at 2026-11-01

Latest source filing: 2026-01-02

Score computed: 2026-11-14

Annual history · FY 2024 · Price history 2025-01-01–2026-11-01

Latest source filing: 2025-06-03

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2025-06-03

Score computed: 2026-11-14

TTM ended 2025-09-30 · Balance sheet at 2025-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2024

Latest source filing: 2026-01-02

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-06-03

Score computed: 2026-11-14

Annual history · FY 2024 · Balance sheet at 2025-09-30

Latest source filing: 2026-01-02

Score computed: 2026-11-14

TTM ended 2025-09-30 · Annual history · FY 2024 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-01-02

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✓ 3✗ 25▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise ValueN/A (EV <= 0)
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=N/A (EV <= 0), ROC=None
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per ShareN/A (negative BVPS)
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessOE Yield=-12008.7%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF Yield
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical Average
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per Share
      ✗Ackman<= 25
      Price vs. Trailing Low100% of trailing low ($0.00)
      ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization+11406.05%; #10/6340 (top 0.2%)
      ✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization-143.4938; #6397/6449 (top 99.2%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+1.4828; #1347/5247 (top 25.7%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-94.64%; #6057/6202 (top 97.7%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✓ 1✗ 11▾

      No clean pass — all 10 investors flag at least one cash flow criterion

      Free Cash Flow Proxy$-3.9M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-1.2M
      ✗LynchPositive and growing
      Operating Cash Flow$-1.1M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-1642.22%, ROA=-5761.36%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF Yield
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/5 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap
      ✗Ackman>= 4%
      Price / FCF per Share
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/10 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✗ 13▾

      All 8 investors flag OWPC's growth

      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: new vs Rev: -35.9%
      ✗LynchInventory growth < Revenue growth
      EPS Growth Direction
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency0/10 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth-35.9%
      ✗Ackman>= 5%
      Positive EPS Growth Frequency
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin -139.3% -> 80.5%, operating margin -1779.5% -> -38494.6%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR
      ✗SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Efficiency0% pass✓ 1✗ 10▾

      No clean pass — all 8 investors flag at least one efficiency criterion

      Current Ratio0.07
      ✗Graham>= 2.0
      ROIC (3-5 yr avg)-945.5%
      ✗Buffett> 10%
      ROIC - WACC-955.5%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)
      ✗Greenblatt> 25%
      Current Ratio Change YoY0.00 -> 0.02
      ✓PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.08x -> 0.07x
      ✗PiotroskiImproved YoY
      Current Assets / Current Liabilities0.07
      ✗Dreman> 1.5
      Return on Invested Capital
      ✗Munger> 15%
      ROIC (high and growing)FY2022: ROIC=unavailable; FY2023: ROIC=unavailable; FY2024: ROIC=unavailable
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROIC
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)
      ✗SleepROIC > 12% in a majority of years
    • Profitability6% pass✓ 4✗ 31▾

      15 of 16 flag OWPC's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)0/11 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)0/11 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-2374.6%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-38494.6% (latest)
      ✗BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-3.9M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROEN/A (negative equity)
      ✗Lynch> 15%
      EBIT / Enterprise ValueN/A (EV <= 0)
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=N/A (EV <= 0), ROC=None
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-5761.36%
      ✗PiotroskiROA > 0
      ROA Change YoY-3998.02% -> -5761.36% (delta: -1763.35%)
      ✗PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-1642.22%, ROA=-5761.36%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY-2181.2% -> 80.5%
      ✓PiotroskiImproved YoY
      Pre-Tax Income / Revenue
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity
      ✗Dreman> 12%
      Margin of Safety
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity-2374.6% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency0/10 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-1916.1%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-1779.5% (2022) -> -38494.6% (2024)
      ✗TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin -139.3% -> 80.5%, operating margin -1779.5% -> -38494.6%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization+11406.05%; #10/6340 (top 0.2%)
      ✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+0.78%; #3370/3702 (top 91.0%)
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-23.3470; #5756/5884 (top 97.8%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/10 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Verdicts7% pass✓ 1✗ 13▾

      Split decision: 13 FAIL · 2 NEUTRAL · 1 PASS

      Overall verdict
      ✗GrahamFAIL (0/9)✗BuffettFAIL (0/9)✗LynchFAIL (0/7)•GreenblattNot ranked✓PiotroskiPASS (F-Score 4)✗DremanFAIL (0/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (0/6)✗MarksFAIL (0/5)✗AckmanFAIL (1/9)✗TempletonFAIL (2/8)✗SleepFAIL (0/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (0/6)✗SchlossFAIL (0/7)•OshaughnessyNEUTRAL (Not ranked)
    • Debt & Leverage8% pass✓ 1✗ 14▾

      11 of 12 flag OWPC's debt & leverage — Graham, Buffett, Lynch +8 more

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest Coverage
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities0.07
      ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt Levels
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-1.7x, D/EBITDA=N/A
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)
      ✗AsnessTop 30% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2024. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Pharmaceutical Products
    SIC Sector: Chemicals & Pharmaceuticals
    Size: Micro Cap($36,032)
    Revenue: $4863.00-35.9% YoY
    Net Income: $3.9M+0.5% YoY

    Financial Snapshot

    Operating Margin-38494.6%
    Return on Equity39.7%
    Debt / Equity--
    Current Ratio0.02
    EPS (Diluted)$-0.04

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2025-09-30

    2024-10-01 – 2025-09-30

    Sources · derived quarter values

    Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, interest expense, operating cash flow.

    Q3 FY 2025

    2025-07-01 – 2025-09-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow.

    Q2 FY 2025

    2025-04-01 – 2025-06-30

    Sources · derived quarter values

    Derived from cumulative filings: interest expense, operating cash flow.

    Q1 FY 2025

    2025-01-01 – 2025-03-31

    Sources
    FY 2024
    Sources
    • 10-K · 2025-06-03
    FY 2023
    Sources
    • 10-K · 2024-05-23
    FY 2022
    Sources
    • 10-K · 2024-05-23
    FY 2021
    Sources
    • 10-K · 2022-04-15
    FY 2020
    Sources
    • 10-K · 2021-04-15
    Market Cap$36.0Kcurrent------$2.4Mest.$3.5Mest.$5.4Mest.$5.5Mest.$13.3Mest.
    Revenue$53.4K$50.0K↑3194%$282↓78%$1.4K↑386%$4.9K↓36%$7.6K↓94%$125.7K↑228%$38.3K↓36%$59.6K
    Operating Income-$1.0M-$377.1K↓1%-$171.1K↑54%-$125.9K↑84%-$1.9M↑10%-$2.1M↑7%-$2.2M↑31%-$3.2M↑59%-$7.9M
    Net Income$4.1M$5.3M↑817%-$265.9K↑69%-$255.7K↑85%-$3.9M-$4.0M↓29%-$3.1M↑19%-$3.8M↑52%-$8.0M
    EPS (Diluted)--$0.04↑540%$-0.00↑80%$0.00↑100%$-0.04↑20%$-0.05$-0.05↑17%$-0.06↑70%$-0.20
    Gross Margin96.1%97.2%↑22%88.3%↑8%78.5%↓5%80.5%↑104%-2181.2%↓1465%-139.3%↓388%48.4%↑164%-75.8%
    Operating Margin-1916.1%-754.8%↑97%-60662.8%↓104%-9183.1%↑97%-38494.6%↓40%-27419.6%↓1441%-1779.5%↑79%-8444.8%↑36%-13291.6%
    ROE-79.5%———39.7%↓16%47.4%↓10%52.4%↓58%124.1%↓70%407.8%
    Total Debt----------$335.0K↓60%$845.5K↑165%$319.3K↓5%$334.8K
    Shareholders' Equity-$5.2M-$5.2M↑47%-$10.4M↓14%-$10.2M↓15%-$9.9M↓19%-$8.3M↓43%-$5.8M↓91%-$3.1M↓56%-$2.0M
    Current Ratio0.070.07↑103%0.07↓54%0.01↓85%0.02↑501%0.00↓94%0.06↓83%0.33↑32%0.25
    Debt / Equity—————-0.04↑72%-0.14↓38%-0.10↑39%-0.17
    Operating Cash Flow-$705.2K-$145.0K↑48%-$396.7K↑17%-$52.1K↑79%-$1.1M↑6%-$1.2M↑13%-$1.4M↑63%-$3.7M↓161%-$1.4M
    Free Cash Flow-----------$1.2M↑16%-$1.4M↑65%-$4.1M↓176%-$1.5M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Pharmaceutical Products

    OWPC vs Peers — Financial Grading

    Revenue$4863.00Bottom 25%
    Net Income$3.9MMedian
    ROE39.7%Top 25%
    D/E—
    Op. Margin-38494.6%Bottom 25%
    Curr. Ratio0.02Bottom 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
    ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
    BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
    BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
    REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
    IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
    NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
    Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11